Evaluating JAK Inhibition in Inflammatory Bowel Disease Management: Considering the Role of Novel Therapeutic Options

PROGRAM CHAIR & FACULTY PRESENTER

Maia Kayal, MD, MS
Assistant Professor
Division of Gastroenterology
Icahn School of Medicine at Mount Sinai
New York, New York

PROGRAM OVERVIEW

This innovative online activity will evaluate the importance of targeting JAK/STAT signaling in IBD from a pathophysiologic perspective and the role of JAK inhibition in modifying therapeutic outcomes. Learn more about key unmet needs in IBD and the relevance of novel therapy in clinical management, as well as about current perspectives in differential diagnosis, clinical assessment and the appropriate choice of effective therapy in IBD management.

TARGET AUDIENCE

This activity is designed to meet the educational needs of gastroenterologists, primary care physicians, nurse practitioners, nurses, pharmacists, and other members of the multidisciplinary team to ensure optimal patient outcomes in the management of IBD.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Evaluate the importance of targeting JAK/STAT signaling in IBD from a pathophysiologic perspective and the role of JAK inhibition in modifying therapeutic outcomes
  • Describe key unmet needs in IBD and the relevance of novel therapy in clinical management
  • Interpret current perspectives in differential diagnosis, clinical assessment and the appropriate choice of effective therapy in IBD management

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hour.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Maia Kayal, MD Advisory Board Fees: Bristol Myers Squibb, Fresenius, and Pfizer
Consulting Fees: AbbVie

All relevant financial relationships have been mitigated.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

  • Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
  • Tara Nelson-Mayfield, MS, Medical Director for Med Learning Group, has nothing to disclose.
  • Jessica McMullen, MPH, Senior Program Manager for Med Learning Group, has nothing to disclose.
  • Laura Aibara, Program Coordinator, for Med Learning Group, has nothing to disclose.
  • Aimee Meissner, Accreditation and Outcomes Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

RELEASED DATE: October 23, 2023
EXPIRATION DATE: October 23, 2024

Copyright © 2022 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Scroll to Top